305 related articles for article (PubMed ID: 11118046)
1. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
2. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.
Schayowitz A; Sabnis G; Goloubeva O; Njar VC; Brodie AM
Br J Cancer; 2010 Sep; 103(7):1001-7. PubMed ID: 20842117
[TBL] [Abstract][Full Text] [Related]
3. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
Comuzzi B; Lambrinidis L; Rogatsch H; Godoy-Tundidor S; Knezevic N; Krhen I; Marekovic Z; Bartsch G; Klocker H; Hobisch A; Culig Z
Am J Pathol; 2003 Jan; 162(1):233-41. PubMed ID: 12507906
[TBL] [Abstract][Full Text] [Related]
4. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
[TBL] [Abstract][Full Text] [Related]
5. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells.
Tillman JE; Yuan J; Gu G; Fazli L; Ghosh R; Flynt AS; Gleave M; Rennie PS; Kasper S
Cancer Res; 2007 May; 67(10):4630-7. PubMed ID: 17510388
[TBL] [Abstract][Full Text] [Related]
6. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP.
Berns EM; de Boer W; Mulder E
Prostate; 1986; 9(3):247-59. PubMed ID: 2946029
[TBL] [Abstract][Full Text] [Related]
7. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation.
Veldscholte J; Berrevoets CA; Brinkmann AO; Grootegoed JA; Mulder E
Biochemistry; 1992 Mar; 31(8):2393-9. PubMed ID: 1540595
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.
Qiao Y; Wang L; Cai LQ; Tan C; Imperato-McGinley J; Zhu YS
J Urol; 2011 Jan; 185(1):305-14. PubMed ID: 21075385
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.
Zhao X; van Steenbrugge GJ; Schröder FH
Urol Res; 1992; 20(3):193-7. PubMed ID: 1615580
[TBL] [Abstract][Full Text] [Related]
11. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins.
Ayub M; Levell MJ
J Steroid Biochem; 1989 Aug; 33(2):251-5. PubMed ID: 2788775
[TBL] [Abstract][Full Text] [Related]
12. Consideration of the use of 17 beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5- alpha-androstan-3-one (4MA), a 5 alpha-reductase inhibitor, in prostate cancer therapy.
Geldof AA; Meulenbroek MF; Dijkstra I; Bohlken S; Rao BR
J Cancer Res Clin Oncol; 1992; 118(1):50-5. PubMed ID: 1729259
[TBL] [Abstract][Full Text] [Related]
13. 17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.
Qiao Y; Zhang ZK; Cai LQ; Tan C; Imperato-McGinley JL; Zhu YS
Prostate; 2007 Dec; 67(16):1719-28. PubMed ID: 17879940
[TBL] [Abstract][Full Text] [Related]
14. The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice.
Andriole GL; Rittmaster RS; Loriaux DL; Kish ML; Linehan WM
Prostate; 1987; 10(3):189-97. PubMed ID: 3588410
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types.
Blok LJ; Themmen AP; Peters AH; Trapman J; Baarends WM; Hoogerbrugge JW; Grootegoed JA
Mol Cell Endocrinol; 1992 Oct; 88(1-3):153-64. PubMed ID: 1334008
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
Gaillard-Moguilewsky M
Urology; 1991; 37(2 Suppl):5-12. PubMed ID: 1992602
[TBL] [Abstract][Full Text] [Related]
17. Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore.
Ochiai K; Yonezawa R; Fujii S
ChemMedChem; 2024 Mar; 19(6):e202400040. PubMed ID: 38291942
[TBL] [Abstract][Full Text] [Related]
18. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.
Veldscholte J; Berrevoets CA; Ris-Stalpers C; Kuiper GG; Jenster G; Trapman J; Brinkmann AO; Mulder E
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):665-9. PubMed ID: 1562539
[TBL] [Abstract][Full Text] [Related]
19. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion.
Schuurmans AL; Bolt J; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):849-53. PubMed ID: 2149505
[TBL] [Abstract][Full Text] [Related]
20. Relationship of androgen receptors to the growth and regression of the prostate.
Rennie PS; Bruchovsky N; Goldenberg SL
Am J Clin Oncol; 1988; 11 Suppl 2():S13-7. PubMed ID: 3071950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
